Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
CH Biotech R&D Co's net current asset value per share for the quarter that ended in Dec. 2025 was NT$-0.17.
The historical rank and industry rank for CH Biotech R&D Co's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of CH Biotech R&D Co was 78.16. The lowest was 78.16. And the median was 78.16.
TPE:6534's Price-to-Net-Current-Asset-Value is not ranked *
in the Agriculture industry.
Industry Median: 3.47 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CH Biotech R&D Co (TPE:6534) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
CH Biotech R&D Co Net Current Asset Value Related Terms
CH Biotech R&D Co Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for CH Biotech R&D Co's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6534 vs CTVA, CF, MOS: Net Current Asset Value Comparison
For the Agricultural Inputs subindustry, CH Biotech R&D Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CH Biotech R&D Co Price-to-Net-Current-Asset-Value vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, CH Biotech R&D Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where CH Biotech R&D Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of NT$-0.17 mean?
CH Biotech R&D Co (TPE:6534) has a Net Current Asset Value of NT$-0.17 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on CH Biotech R&D Co and its competitors. Over the past decade, CH Biotech R&D Co's Net Current Asset Value has ranged from 78.16 to 78.16. According to the industry distribution chart, CH Biotech R&D Co ranks #999999 out of 163 companies in the Agriculture industry.
Is CH Biotech R&D Co's Net Current Asset Value too high?
CH Biotech R&D Co's current Net Current Asset Value is NT$-0.17. Over the past 10 years, this metric has ranged from a low of 78.16 to a high of 78.16. Based on the distribution chart, CH Biotech R&D Co ranks #999999 out of 163 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, CH Biotech R&D Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's Net Current Asset Value compare to CTVA and CF?
According to the Agriculture industry distribution chart, CH Biotech R&D Co ranks #999999 out of 163 companies for Net Current Asset Value. This places CH Biotech R&D Co in the lower half of its industry. The industry median Net Current Asset Value is 3.47. Historically, CH Biotech R&D Co's own Net Current Asset Value has ranged from 78.16 to 78.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for an Agriculture company?
The median Net Current Asset Value among Agriculture companies is 3.47, based on 163 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on CH Biotech R&D Co and its competitors. For the Agriculture industry, the median Net Current Asset Value is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CH Biotech R&D Co's current Net Current Asset Value is NT$-0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Fairly Valued. The stock's GF Value™ is NT$100.70, compared to a current price of NT$93.50 — trading 7.1% below its estimated fair value. The current Net Current Asset Value is NT$-0.17. CH Biotech R&D Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current Net Current Asset Value is NT$-0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?
Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued.
The current stock price of NT$93.50 is trading 7.1% below its estimated GF Value™ of NT$100.70.
GuruFocus considers CH Biotech R&D Co to be Fairly Valued.
Key valuation signals for TPE:6534:
Net Current Asset Value: NT$-0.17
GF Value™: NT$100.70 vs. price of NT$93.50 (7.1% below fair value)
No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
84GF Score
Get the complete analysis for TPE:6534
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6534 has been successfully added to your 
